

ESTIMATED ANNUALIZED BURDEN HOURS—Continued

Type of respondents	Form No. and name	Number of respondents	Number of responses per respondent	Average burden per response (in hrs.)
Medical/Clinical Laboratory Technologist	57.305: Hemovigilance Incident	500	12	10/60
Staff RN	57.400: Outpatient Procedure Component—Annual Facility Survey.	5,000	1	5/60
Staff RN	57.401: Outpatient Procedure Component—Monthly Reporting Plan.	5,000	12	15/60
Staff RN	57.402: Outpatient Procedure Component Event.	5,000	25	40/60
Staff RN	57.403: Outpatient Procedure Component—Monthly Denominators and Summary.	5,000	12	40/60
Registered Nurse (Infection Preventionist)	57.500: Outpatient Dialysis Center Practices Survey.	6,000	1	1.75
Staff RN	57.501: Dialysis Monthly Reporting Plan	6,000	12	5/60
Staff RN	57.502: Dialysis Event	6,000	60	13/60
Staff RN	57.503: Denominator for Outpatient Dialysis	6,000	12	6/60
Staff RN	57.504: Prevention Process Measures Monthly Monitoring for Dialysis.	600	12	30/60
Staff RN	57.505: Dialysis Patient Influenza Vaccination.	250	75	10/60
Staff RN	57.506: Dialysis Patient Influenza Vaccination Denominator.	250	5	10/60
Epidemiologist	57.600: State Health Department Validation Record.	152	50	15/60

Kimberly S. Lane,

Deputy Director, Office of Scientific Integrity, Office of the Associate Director for Science, Office of the Director, Centers for Disease Control and Prevention.

[FR Doc. 2013–20609 Filed 8–22–13; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Initial Review

The meeting announced below concerns Impact of Japanese Encephalitis Vaccination in Cambodia, Funding Opportunity Announcement (FOA) CK14–001, initial review.

In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the aforementioned meeting:

Time and Date: 1:00 p.m.–3:00 p.m., October 17, 2013 (Closed).

Place: Teleconference.

Status: The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c) (4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92–463.

Matters To Be Discussed: The meeting will include the initial review,

discussion, and evaluation of applications received in response to “Impact of Japanese Encephalitis Vaccination in Cambodia, FOA CK14–001”.

Contact Person for More Information: Gregory Anderson, M.S., M.P.H., Scientific Review Officer, CDC, 1600 Clifton Road NE., Mailstop E60, Atlanta, Georgia 30333, Telephone: (404) 718–8833.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Elaine L. Baker,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 2013–20531 Filed 8–22–13; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2013–N–0002]

Withdrawal of Approval of New Animal Drug Applications; Quali-Tech Products, Inc.; Bambermycins; Pyrantel; Tylosin; Virginiamycin

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of four new animal drug applications (NADAs) held by Quali-Tech Products, Inc., at the sponsor's request because the products are no longer manufactured or marketed.

DATES: Withdrawal of approval is effective September 3, 2013.

FOR FURTHER INFORMATION CONTACT: David Alterman, Center for Veterinary Medicine (HFV–212), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855; 240–453–6843; email: david.alterman@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: Quali-Tech Products, Inc., has requested that FDA withdraw approval of the following four NADAs because the products, used to manufacture Type C medicated feeds, are no longer manufactured or marketed: NADA 097–980 for Quali-Tech TYLAN–10 (tylosin phosphate) Premix, NADA 118–815 for Q.T. BAN–TECH (pyrantel tartrate), NADA 132–705 for FLAVOMYCIN (bambermycins), and NADA 133–335 for STAFAC (virginiamycin) Swine Pak 10.

Therefore, under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, and in accordance with § 514.116 *Notice of withdrawal of approval of application* (21 CFR 514.116), notice is given that approval of NADAs 097–980, 118–815, 132–705, and 133–335, and all supplements and